Poul Henning Jensen

Alpha synuclein in Parkinson's disease

Research output: Contribution to book/anthology/report/proceedingReviewResearch

  • Christine Lund Kragh, Denmark
  • Marina Romero-Ramos
  • Glenda M Halliday, Neuroscience Research Australia, Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia., Denmark
  • Poul Henning Jensen
The perception of Parkinson’s disease (PD) as a disease centered on dopaminergic
striatonigral neurodegeneration has changed fundamentally since 1997 when
the first mutation in the SNCA gene (PARK1) encoding a-synuclein was discovered
(Polymeropoulos et al. 1997). This discovery formed the basis for a new
description of brain pathology characterized by the presence of a-synuclein aggregates in brain cell inclusions that are the hallmarks of PD and other
synucleinopathies: dementia with Lewy bodies (DLB) and multiple system
atrophy (MSA). This field has been thoroughly covered by many reviews during
the last decade (Gai et al. 1998; Spillantini and Goedert 2000; Huang et al. 2004;
Ubhi et al. 2011). This review will briefly highlight the historical breakthroughs
but focus on a-synuclein modifications, human neuropathology, biomarker
potential, current animal models and the new concepts emerging after the
significance of extracellular a-synuclein has gained support.
Original languageEnglish
Title of host publicationHandbook of Neurotoxicity
EditorsRichard M. Kostrzewa
Place of publicationNew York
PublisherSpringer Science+Business Media
Publication year2014
Pages691-726
Chapter23
ISBN (print)978-1-4614-5835-7
ISBN (Electronic) 978-1-4614-5836-4
DOIs
Publication statusPublished - 2014

See relations at Aarhus University Citationformats

ID: 93891094